F
Fabio Guarracino
Researcher at University of Pisa
Publications - 258
Citations - 7471
Fabio Guarracino is an academic researcher from University of Pisa. The author has contributed to research in topics: Levosimendan & Intensive care. The author has an hindex of 44, co-authored 230 publications receiving 6188 citations. Previous affiliations of Fabio Guarracino include Vita-Salute San Raffaele University & University of Milan.
Papers
More filters
Journal ArticleDOI
Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.
Andrea Morelli,Christian Ertmer,Martin Westphal,Sebastian Rehberg,Tim Kampmeier,Sandra Ligges,Alessandra Orecchioni,Annalia D'Egidio,Fiorella D’Ippoliti,Cristina Raffone,Mario Venditti,Fabio Guarracino,Massimo Girardis,Luigi Tritapepe,Paolo Pietropaoli,Alexander Mebazaa,Mervyn Singer +16 more
TL;DR: Targeted heart rates were achieved in all patients in the esmolol group compared with those in the control group and no clinically relevant differences between groups in other cardiopulmonary variables nor in rescue therapy requirements were found.
Journal ArticleDOI
International Evidence-Based Recommendations for Focused Cardiac Ultrasound
Gabriele Via,Arif Hussain,Mike Wells,Robert F. Reardon,Mahmoud Elbarbary,Vicki E. Noble,James W. Tsung,Aleksandar N. Neskovic,Susanna Price,Achikam Oren-Grinberg,Andrew S. Liteplo,Ricardo Cordioli,Nitha Naqvi,Philippe Rola,Jan Poelaert,Tatjana Golob Guliĉ,Erik Sloth,Arthur J. Labovitz,Bruce J. Kimura,Raoul Breitkreutz,Navroz Masani,Justin Bowra,Daniel Talmor,Fabio Guarracino,Adrian Goudie,Wang Xiaoting,Rajesh Chawla,Maurizio Galderisi,Micheal Blaivas,Tomislav Petrovic,Enrico Storti,Luca Neri,Lawrence Melniker +32 more
TL;DR: For the first time, evidence-based clinical recommendations comprehensively address this branch of point-of-care ultrasound, providing a framework for FoCUS to standardize its application in different clinical settings around the world.
Journal ArticleDOI
Desflurane and Sevoflurane in Cardiac Surgery: A Meta-Analysis of Randomized Clinical Trials
Giovanni Landoni,Giuseppe Biondi-Zoccai,Alberto Zangrillo,Elena Bignami,Stefania D'Avolio,C. Marchetti,Maria Grazia Calabrò,O. Fochi,Fabio Guarracino,Luigi Tritapepe,Stefan De Hert,G. Torri +11 more
TL;DR: The present data show for the first time that the choice of an anesthetic regimen based on administration of halogenated anesthetics is associated with a better outcome after cardiac surgery.
Journal ArticleDOI
Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan.
Zoltán Papp,István Édes,Sonja Fruhwald,Stefan De Hert,Markku Salmenperä,Heli Leppikangas,Alexandre Mebazaa,Giovanni Landoni,Elena Grossini,Philippe Primo Caimmi,Andrea Morelli,Fabio Guarracino,Robert H. G. Schwinger,S. Meyer,Lars Algotsson,Bernt Gerhard Wikström,Kirsten Jørgensen,Gerasimos Filippatos,John Parissis,Martín J. García González,Alexander Parkhomenko,Mehmet Yilmaz,Matti Kivikko,Piero Pollesello,Ferenc Follath +24 more
TL;DR: The data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators.
Journal ArticleDOI
Levosimendan for Hemodynamic Support after Cardiac Surgery
Giovanni Landoni,Vladimir V. Lomivorotov,Gabriele Alvaro,Rosetta Lobreglio,Antonio Pisano,Fabio Guarracino,Maria Grazia Calabrò,Evgeny Grigoryev,Valery Likhvantsev,Marcello Fonseca Salgado-Filho,Alessandro Bianchi,Vadim Pasyuga,Massimo Baiocchi,Federico Pappalardo,Fabrizio Monaco,Vladimir A. Boboshko,Marat N Abubakirov,Bruno Amantea,Rosalba Lembo,Luca Brazzi,Luigi Verniero,Pietro Bertini,Anna Mara Scandroglio,Tiziana Bove,Alessandro Belletti,Maria G Michienzi,Dmitriy L Shukevich,Tatiana S. Zabelina,Rinaldo Bellomo,Alberto Zangrillo +29 more
TL;DR: In patients who required perioperative hemodynamic support after cardiac surgery, low‐dose levosimendan in addition to standard care did not result in lower 30‐day mortality than placebo and there was no significant difference in rates of hypotension or cardiac arrhythmias.